Recent News & Research

lungevity
Advocacy

Advocacy 101: Intro to Advocacy

*March 2024* Sharing your stories and experiences as someone impacted by lung cancer can help create positive change. Whether you are a patient, survivor, caregiver, healthcare provider, family member, or friend, adding your voice as a lung cancer advocate can help humanize important issues and statistics for policymakers and decision-makers.…
laurabbook@gmail.com
July 8, 2024
OncoDaily
Advocacy

Jill Feldman Awarded the 2024 ASCO Patient Advocate Award

*March 2024* The American Society of Clinical Oncology (ASCO) has announced Jill Feldman, as the recipient of the 2024 ASCO Patient Advocate Award. This award acknowledges Dr. Newman’s dedication and contributions to the field of global oncology. Jill Feldman, is a lung cancer patient and passionate advocate with a personal connection to the cause.…
laurabbook@gmail.com
July 8, 2024
journal of clinical oncology logo
ResearchTreatments

Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership

*February 2024* Abstract Patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer represent a distinct subgroup of individuals who can experience initially tolerable and durable effects with first-line EGFR-directed tyrosine kinase inhibitors. Unfortunately, acquired treatment resistance and cancer progression within the CNS are inevitable during the disease course and present…
laurabbook@gmail.com
July 8, 2024
Lung Cancer Journal
ResearchTreatments

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

*April 2024* Highlights Additional frontline options for treating EGFR-mutated NSCLC are required. Lazertinib showed promising efficacy and safety in LASER201 and LASER301 trial. Long-term follow-up in LASER201 showed long PFS and OS with frontline lazertinib. Patients with and without baseline brain metastasis showed clinical benefit. Lazertinib was well tolerated, consistent…
laurabbook@gmail.com
July 8, 2024
ESMO Open Cancer Horizons
ResearchTreatments

Efficacy and safety of intrathecal pemetrexed (IP) for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial

*April 2024* IP is an effective treatment method for the EGFR-TKI-failed NSCLC-LM with a median OS of 12 months. Previous intrathecal methotrexate/cytarabine and whole-brain radiotherapy didn't have significant difference on IP treatment. IP is a safe treatment method for the EGFR-TKI-failed NSCLC-LM with tolerated adverse events. IP should be recommended…
laurabbook@gmail.com
July 8, 2024
Science Direct
ResearchTreatments

Primary and acquired resistance to first-line Osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

*April 2024* Highlights Osimertinib is currently the common first-line therapy in EGFR-mutated non-small cell lung cancer patients. Understanding primary and acquired resistance mechanisms to osimertinib is crucial in choosing subsequent therapy strategy. Treatment after osimertinib must be tailored according to type of progression and detection of resistance mechanisms. Therapeutic strategies targeting…
laurabbook@gmail.com
July 8, 2024
journal of thoracic oncology
ResearchTreatments

Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC

*February 2024* Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor that holds substantial importance in understanding the disease progression and guiding treatment strategies. Tumor cells acquire somatic mutations in both oncogenes and tumor suppressor genes (TSGs) leading to tumorigenesis.1  The event of multiple mutations emerging…
laurabbook@gmail.com
July 7, 2024